SG11201704767YA - Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor - Google Patents

Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor

Info

Publication number
SG11201704767YA
SG11201704767YA SG11201704767YA SG11201704767YA SG11201704767YA SG 11201704767Y A SG11201704767Y A SG 11201704767YA SG 11201704767Y A SG11201704767Y A SG 11201704767YA SG 11201704767Y A SG11201704767Y A SG 11201704767YA SG 11201704767Y A SG11201704767Y A SG 11201704767YA
Authority
SG
Singapore
Prior art keywords
dihydro
oxo
combination
egfr inhibitor
cancer activity
Prior art date
Application number
SG11201704767YA
Other languages
English (en)
Inventor
Friedhelm Bladt
Manja Friese-Hamim
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52133768&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201704767Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG11201704767YA publication Critical patent/SG11201704767YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201704767YA 2014-12-12 2015-11-12 Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor SG11201704767YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14004200 2014-12-12
PCT/EP2015/002265 WO2016091346A1 (en) 2014-12-12 2015-11-12 Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor

Publications (1)

Publication Number Publication Date
SG11201704767YA true SG11201704767YA (en) 2017-07-28

Family

ID=52133768

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201704767YA SG11201704767YA (en) 2014-12-12 2015-11-12 Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor

Country Status (17)

Country Link
US (2) US10532052B2 (uk)
EP (1) EP3229806A1 (uk)
JP (1) JP2017537939A (uk)
KR (1) KR20170090499A (uk)
CN (1) CN106999493A (uk)
AU (1) AU2015360005A1 (uk)
BR (1) BR112017012136A2 (uk)
CA (1) CA2970391A1 (uk)
CL (1) CL2017001478A1 (uk)
IL (1) IL252752A0 (uk)
MX (1) MX2017007372A (uk)
PH (1) PH12017500718A1 (uk)
RU (1) RU2017124612A (uk)
SG (1) SG11201704767YA (uk)
UA (1) UA120108C2 (uk)
WO (1) WO2016091346A1 (uk)
ZA (1) ZA201704654B (uk)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3231793T3 (pl) 2014-12-12 2020-07-27 Japan Tobacco Inc. Związki dihydropirymidyn-2-onu i ich zastosowania medyczne
AR114270A1 (es) 2018-02-28 2020-08-12 Japan Tobacco Inc Compuestos de 4-metildihidropirimidinona y su uso farmacéutico
US11455294B2 (en) * 2019-10-18 2022-09-27 Sap Se Information lifecycle management notification framework

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090155247A1 (en) 2005-02-18 2009-06-18 Ashkenazi Avi J Methods of Using Death Receptor Agonists and EGFR Inhibitors
US20060188498A1 (en) 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
AU2009300328A1 (en) * 2008-10-01 2010-04-08 Ludwig Institute For Cancer Research Methods for the treatment of cancer
SG172831A1 (en) 2009-01-08 2011-08-29 Merck Patent Gmbh Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
WO2012061299A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
WO2013138495A1 (en) * 2012-03-15 2013-09-19 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
WO2013139423A1 (en) 2012-03-19 2013-09-26 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds
ES2894830T3 (es) * 2012-04-03 2022-02-16 Novartis Ag Productos combinados con inhibidores de tirosina·cinasa y su uso
KR102157501B1 (ko) 2012-10-11 2020-09-18 메르크 파텐트 게엠베하 항암 활성을 갖는 6-옥소-1,6-디히드로-피리다진 유도체와 ｍｅｋ 억제제와의 조합
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته

Also Published As

Publication number Publication date
US20170319581A1 (en) 2017-11-09
US10532052B2 (en) 2020-01-14
MX2017007372A (es) 2017-11-06
JP2017537939A (ja) 2017-12-21
CL2017001478A1 (es) 2018-01-05
PH12017500718A1 (en) 2017-10-09
CN106999493A (zh) 2017-08-01
EP3229806A1 (en) 2017-10-18
RU2017124612A3 (uk) 2019-06-05
UA120108C2 (uk) 2019-10-10
WO2016091346A1 (en) 2016-06-16
ZA201704654B (en) 2019-08-28
CA2970391A1 (en) 2016-06-16
AU2015360005A1 (en) 2017-07-27
US20190388423A1 (en) 2019-12-26
IL252752A0 (en) 2017-08-31
BR112017012136A2 (pt) 2018-01-02
RU2017124612A (ru) 2019-01-14
KR20170090499A (ko) 2017-08-07

Similar Documents

Publication Publication Date Title
EP3111310A4 (en) Zone grouping
AU358453S (en) Furniture
EP3187492A4 (en) Pyrimidinone derivative having autotaxin-inhibitory activity
EP3146495A4 (en) Generating activity summaries
PL2923589T3 (pl) Urządzenie do palenia tytoniu
SG11201606851WA (en) Burner
SG11201609205WA (en) Heterocyclyl-butanamide derivatives
IL248785A0 (en) History of carboxamide
GB201419877D0 (en) Burner
PL3131898T3 (pl) Pochodne fluoroalkilofluorenu
AP2016009554A0 (en) Carboxamide derivatives
HK1246264A1 (zh) 催化燃燒器設備
PL3418273T3 (pl) Pochodne flawaglin
IL248773A0 (en) History of naphthyridinedione
IL248629B (en) Substances containing diheteroaryl conjugated to cycloalkyl and their uses
PL2924380T3 (pl) Palnik dodatkowy
EP3181554A4 (en) Quinazoline derivative
PL3380552T3 (pl) Bchpc o zmniejszonej szybkości spalania
ZA201704654B (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor
ZA201704621B (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative
PL3119744T3 (pl) Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
GB201406237D0 (en) A securable furniture arrangement
SG11201605498VA (en) Combination of a 6-oxo- 1,6-dihydro-pyridazine derivate having anti-cancer activity with gefitinib
SG11201704507YA (en) Rivet
IL248801A0 (en) Carboxamide history